SYDNEY, AUSTRALIA: Next Science Limited (ASX: NXS), a leading medical technology company dedicated to combating biofilm-based infections in human health, has announced the appointment of Harry Thomas Hall, IV, widely known as “I.V.,” as its new Managing Director and Chief Executive Officer (CEO).
I.V. will assume the role of CEO on July 10, 2023. To facilitate a smooth transition, the current CEO, Judith Mitchell, will remain with the company until the end of July.
Bringing with him 28 years of experience in the global medical device industry, I.V. has held various general management positions, encompassing product development, global strategic marketing, commercial operations, and sales leadership. His career began in 1997 at DePuy Synthes, a subsidiary of Johnson and Johnson (NYSE: JNJ), where he assumed senior roles, including Global Vice President for MedTech R&D and Worldwide President for Trauma, Extremities, Craniomaxillofacial & Animal Health.
Notably, I.V. served as a member of the Global Leadership Team and R&D Leadership Team for DePuy Synthes, overseeing the successful launch of the first surgical robot developed by JNJ / DePuy Synthes. During his tenure as Worldwide President for Trauma, Extremities, Craniomaxillofacial, and Animal Health, I.V. managed a global portfolio and executed a strategy for a platform worth USD 3.2 billion in the Global Orthopaedic Unit of DePuy Synthes. He led a team of over 1,100 professionals across sales, marketing, and R&D, establishing strong relationships with numerous key opinion leaders worldwide.
The appointment of I.V. as the new CEO marks a significant milestone for Next Science. His extensive experience and expertise in the medical device industry position him well to lead the company’s continued growth and expansion in combating biofilm-based infections. The board of directors and shareholders of Next Science expressed confidence in I.V.’s ability to drive the company forward and build upon its success under the leadership of Judith Mitchell.
Next Science Limited remains committed to developing innovative solutions to address the impact of biofilm-based infections on human health, and with I.V. at the helm, the company aims to further advance its proprietary XBIOTM suite of products and make a lasting impact in the medical technology sector.
Leave a Reply